{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:19:30Z","timestamp":1762917570393,"version":"3.40.5"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jconrel.2014.09.032","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T18:18:24Z","timestamp":1413483504000},"page":"197-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation"],"prefix":"10.1016","volume":"196","author":[{"given":"Benjamin M.","family":"Wohl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton A.A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E.B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9864-321X","authenticated-orcid":false,"given":"Alexander N.","family":"Zelikin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.09.032_bb0005","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","article-title":"The design of drugs for HIV and HCV","volume":"6","author":"De Clercq","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0015","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/COH.0b013e32834b87f8","article-title":"Future of hepatitis C therapy: development of direct-acting antivirals","volume":"6","author":"Dore","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2004-832928","article-title":"Treatment of chronic hepatitis C infection with peginterferons plus ribavirin","volume":"24","author":"Fried","year":"2004","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/AAC.30.2.201","article-title":"Biochemistry and clinical applications of ribavirin","volume":"30","author":"Gilbert","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0030","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/cmdc.200700159","article-title":"Prodrug strategies in anticancer chemotherapy","volume":"3","author":"Kratz","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","article-title":"HPMA copolymers: origins, early developments, present, and future","volume":"62","author":"Kopecek","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0050","first-page":"357","article-title":"Ribavirin conjugated with lactosaminated poly-l-lysine. Selective delivery to the liver and increased antiviral activity in mice with viral hepatitis","volume":"54","author":"Di Stefano","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.21072","article-title":"Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity","volume":"43","author":"Levy","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0060","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/adhm.201300637","article-title":"Macromolecular prodrugs of ribavirin: concerted efforts of the carrier and the drug","volume":"3","author":"Smith","year":"2014","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0065","doi-asserted-by":"crossref","DOI":"10.1039\/C4PY00624K","article-title":"Macromolecular (pro)drugs in antiviral research","author":"Smith","year":"2014","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/anie.200801951","article-title":"Synthesis of functional polymers by post-polymerization modification","volume":"48","author":"Gauthier","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0075","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10529-005-5188-x","article-title":"Regioselective enzymatic acylation of ribavirin to give potential multifunctional derivatives","volume":"27","author":"Liu","year":"2005","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0080","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/pola.22606","article-title":"Novel hepatoma-targeting micelles based on chemo-enzymatic synthesis and self-assembly of galactose-functionalized ribavirin-containing amphiphilic random copolymer","volume":"46","author":"Li","year":"2008","journal-title":"J. Polym. Sci. A Polym. Chem."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mabi.201300244","article-title":"Macromolecular prodrugs for controlled delivery of ribavirin","volume":"14","author":"Kryger","year":"2013","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0090","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1039\/c3cc00315a","article-title":"Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug","volume":"49","author":"Kryger","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0095","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/bm401048s","article-title":"Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs","volume":"14","author":"Wohl","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0105","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","article-title":"Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication","volume":"76","author":"Blight","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0110","article-title":"Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells","author":"Ruiz-Sanchis","year":"2014","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000050085","article-title":"Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load","volume":"45","author":"Tsubota","year":"2002","journal-title":"Intervirology"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0120","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0140-6736(91)91077-8","article-title":"Ribavirin for HIV","volume":"338","author":"De Clercq","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1476-5586(03)80011-8","article-title":"Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function","volume":"5","author":"Kast","year":"2003","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1365-2567.2000.00142.x","article-title":"Nitric oxide and virus infection","volume":"101","author":"Akaike","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0140","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1021\/ma047611m","article-title":"Reversible addition\u2013fragmentation chain transfer polymerization: end group modification for functionalized polymers and chain transfer agent recovery","volume":"38","author":"Perrier","year":"2005","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0145","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0039-9140(01)00323-X","article-title":"Detection and determination of nitrate and nitrite: a review","volume":"54","author":"Moorcroft","year":"2001","journal-title":"Talanta"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00172772","article-title":"Nitric oxide synthase: expression and expressional control of the three isoforms","volume":"352","author":"Forstermann","year":"1995","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1096\/fj.06-6779com","article-title":"Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion","volume":"21","author":"Michaelis","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0160","doi-asserted-by":"crossref","first-page":"16058","DOI":"10.1074\/jbc.M602219200","article-title":"Nitric oxide signaling via nuclearized endothelial nitric-oxide synthase modulates expression of the immediate early genes iNOS and mPGES-1","volume":"281","author":"Gobeil","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/bm901129x","article-title":"In vitro cytotoxicity of RAFT polymers","volume":"11","author":"Pissuwan","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0170","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1039\/b904456f","article-title":"Differences in cytotoxicity of poly(PEGA)s synthesized by reversible addition\u2013fragmentation chain transfer polymerization","author":"Chang","year":"2009","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0175","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/JVI.2.9.878-885.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro","volume":"2","author":"De Somer","year":"1968","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0180","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/JVI.2.9.886-893.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo","volume":"2","author":"De Somer","year":"1968","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0185","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-2427(98)00188-3","article-title":"Effect of various adjuvants on secondary immune response in chickens","volume":"66","author":"Hilgers","year":"1998","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0190","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1021\/ma062919u","article-title":"Thiocarbonylthio end group removal from RAFT-synthesized polymers by radical-induced reduction","volume":"40","author":"Chong","year":"2007","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0195","article-title":"Polymers fight HIV: potent (pro)drugs identified through parallel automated synthesis","author":"Zuwala","year":"2014","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0200","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s13233-012-0022-5","article-title":"Effect of bond linkage on in vitro drug release and anti-HIV activity of chitosan\u2013stavudine conjugates","volume":"20","author":"Zeng","year":"2012","journal-title":"Macromol. Res."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0205","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cmdc.201000352","article-title":"Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3\u2032-azido-3\u2032-deoxythymidine (AZT, Zidovudine)","volume":"5","author":"Li","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bmc.2009.11.013","article-title":"Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan\u2013O-isopropyl-5\u2032-O-d4T monophosphate conjugate","volume":"18","author":"Yang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0215","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/jm010969d","article-title":"Synthesis of new covalently bound kappa-carrageenan\u2013AZT conjugates with improved anti-HIV activities","volume":"45","author":"Vlieghe","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0220","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.addr.2003.10.039","article-title":"Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules","volume":"56","author":"Yessine","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2011.06.015","article-title":"Biodegradable star HPMA polymer\u2013drug conjugates: biodegradability, distribution and anti-tumor efficacy","volume":"154","author":"Etrych","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0230","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14656560903580001","article-title":"Role of ribavirin in HCV treatment response: now and in the future","volume":"11","author":"Jain","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0235","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1128\/JCM.43.11.5679-5684.2005","article-title":"Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system","volume":"43","author":"Kato","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0240","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1124\/mol.58.5.1100","article-title":"Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase\/integrase) in the virus replicative cycle","volume":"58","author":"Witvrouw","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0166-3542(02)00054-2","article-title":"Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication","volume":"55","author":"Gong","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2011.03.176","article-title":"The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1","volume":"90","author":"Pirrone","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0255","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.addr.2007.11.009","article-title":"Polymer\u2013drug conjugates: recent development in clinical oncology","volume":"60","author":"Li","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.09.032_bb0260","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.drudis.2013.09.007","article-title":"Polymer\u2013drug conjugates: present state of play and future perspectives","volume":"18","author":"Pang","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0265","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jconrel.2014.05.001","article-title":"Polymer therapeutics: top 10 selling pharmaceuticals \u2014 what next?","volume":"190","author":"Duncan","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.09.032_bb0270","article-title":"Macromolecular prodrugs of ribavirin: Towards a treatment for co-infection with HIV and HCV","author":"Smith","year":"2014","journal-title":"Chem. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914006816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914006816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T22:00:34Z","timestamp":1598392834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914006816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":54,"alternative-id":["S0168365914006816"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.09.032","relation":{},"ISSN":["0168-3659"],"issn-type":[{"type":"print","value":"0168-3659"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}